Novaccess Global Inc. · OTC:XSNX
Novaccess Global — Investor Presentation (February 2023)
18 slides from Novaccess Global's investor presentation, February 2023
Slide 1: Confidential and Proprietary. Copyright 2022 NovAccess Global, Inc. All Rights Reserved.
Confidential and Proprietary. Copyright 2022 NovAccess Global, Inc. All Rights Reserved.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This information package contains forward-looking statements, which includes forecasts and timelines. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “will”, “proposes”, “expects”, “estimates”, “intends”, “anticipate
Slide 3: About Us
About About Us Us Pre-IND stage biotech company developing novel, personalized immunotherapies for brain cancers Orphan drug-designated, platform technology - TLR-AD1 2026, US, 2.9 Billion Market Size (GlobalData Inc. 2019) An expert scientific and managerial team focused on bringing novel cancer th
Slide 4: Our Focused Mission
Our Focused Mission Growth by acquisition of cutting-edge assets Enhance and accelerate bringing to market novel brain Utilization of our expert tumor immunotherapies executive and scientific advisory board 4 Confidential and Proprietary. Copyright 2022 NovAccess Global, Inc. All Rights Reserved.
Slide 5: Our Team
Our Team Each Contributor, an Expert in their Field - Highly Focused, yet Adaptable Management Board of Directors Scientific Advisory Board John Cassarini Portfolio Management Renard Currie MBA Andrew Norris Ph.D. Dwain Irvin Ph.D., MPH Executive, XSNX Board Manages product portfolio for Co-Founder,
Slide 6: Glioblastoma Facts
Glioblastoma Facts • More than 21,000 brain tumors diagnoses are estimated annually in the U.S. • Glioblastoma is the most common primary adult brain tumor (e.g. Ted Kennedy, John McCain) • Five-year survival rates are less than 5% for Glioblastoma • Despite 40-year advances in Chemotherapy and Radi
Slide 7: Immunotherapy for Glioblastoma
Immunotherapy for Glioblastoma Problem: • Standard of Care: Surgical resection followed by radiation and chemotherapy • 15-month median survival • No Cures: Significant unmet need Solution: • Immunotherapy: 3 Major Types 1. Dendritic Cell (DC) 2. Checkpoint Inhibitors 3. T-Cell ▷ All immunotherapy a
Slide 8: Dendritic Cell Vaccine (1st Generation)
Immunotherapy for Glioblastoma Dendritic Cell Vaccine (1st Generation) • Improves survival in responders (Phase I and II) • Not a cure - Reduces chance of Glioblastoma recurrence • Needs improvement-survival rates, outcomes 8 Confidential and Proprietary. Copyright 2022 NovAccess Global, Inc. All Ri
Slide 9: 3rd Generation Immunotherapy: TLR-AD1
Immunotherapy for Glioblastoma 3rd Generation Immunotherapy: TLR-AD1 • 3rd Generation ‣ 35% improvement over 1st generation in animals • 1st and 2nd Generation ‣ Improves survival in Glioblastoma responders (Phase I, II) * NOT a cure – Reduces chance of Glioblastoma recurrence 9 Confidential and Pro
Slide 10: Step 1: Isolate Tumor and Immune Cells
Immunotherapy for Glioblastoma Step 1: Neurosurgeon isolates Tumor and Immune Cells - Sends to Lab TUMOR TUMOR ANTIGEN CELLS BLOOD ANTIGEN- PRESENTING CELLS (Dendritic Immune Cells) 10 Confidential and Proprietary. Copyright 2022 NovAccess Global, Inc. All Rights Reserved.
Slide 11: Step 2: Process Tumor Antigens with TLR-AD1
Immunotherapy for Glioblastoma Step 2: Immune Cells Process Tumor Antigens Utilizing TLR-AD1 Technology TUMOR ANTIGEN CELLS (Bulk Tumor Lysate) ANTIGEN-PRESENTING CELLS (Dendritic Immune Cells) 11 Confidential and Proprietary. Copyright 2022 NovAccess Global, Inc. All Rights Reserved.
Slide 12: Step 3: TLR-AD1 Vaccine Administered
Immunotherapy for Glioblastoma Step 3: TLR-AD1 Glioblastoma Vaccine Administered Glioma Tumor Cell Lysate Antigen specific or antigens derived from bulk lysate combined with Toll- like receptor (TLR) adjuvants ‘Intelligence-Briefed’ Immune Cells Introduced into Bloodstream T-Cells Trained to Identif
Slide 13: Summary
Summary • Parent immunotherapy shows improvement in patient survival over standard of care (chemotherapy and radiation) in Phase I and II Human Clinical trials. • TLR-AD1 out-performs parent immunotherapies in pre-clinical animal trials. • FDA provides Orphan Drug designation for TLR-AD1, covering a
Slide 14: Market Analysis
Immunotherapy for Glioblastoma Market Analysis: • 2018, Global, $700M Glioblastoma Treatment Market, CAGR 9.3% (GlobalData Inc. 2019) • 2027, US, $2.9B Glioblastoma Treatment Market (GlobalData Inc. 2019) • Unmet need - No current immunotherapy for brain tumors • Presumed significant market opportun
Slide 15: Company Highlights
Company Highlights • Filing IND application to obtain FDA approval for human clinical trial 2023 • Uplist to Nasdaq YE 2022 Partnering with manufacturing company Acquisition of cutting-edge assets in oncology Q4 2022 FDA provides Orphan Drug Designation for TLR-AD1 Q3 2022 Uplisted on OTC Markets (O
Slide 16: Milestones Achieved
Milestones Achieved Initiated recapitalization of company; expected to be completed with diversification of 2022 shareholder base as XSNX shares are distributed to Innovest shareholders FDA pre-IND interaction: FDA states that XSNX is not required to do additional pre-clinical 2021 R&D studies and p
Slide 17: Investor Highlights
Investor Highlights Orphan Drug-Designation in October 2022 Announce Manufacturing Partner 2023 Complete Manufacturing Data for IND Application 2023 File IND application with FDA in 2023 Glioblastoma Treatment Market Predicted to be Valued over $2.9B annually by 2027 Confidential 2022 17 Confidentia
Slide 18: Thank You!
Thank You! Confidential and Proprietary. Copyright 2022 NovAccess Global, Inc. All Rights Reserved. novaccessglobal.com
NovAccess Global — Investor Presentation (February 2023) on 6ix